SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn
- PMID: 27874994
- PMCID: PMC5401975
- DOI: 10.1111/bcp.13194
SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn
Abstract
Aim: The use of selective serotonin reuptake inhibitors (SSRIs) in late pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN). Limited data are available on the risk of PPHN associated with serotonin norepinephrine reuptake inhibitors (SNRIs). We aimed to quantify both associations.
Methods: Using data from the Quebec Pregnancy Cohort between 1998 and 2009, we included women covered by the provincial drug plan who had a singleton live birth. Exposure categories were SSRI, SNRI and other antidepressant use; non-users were considered as the reference category. Generalized estimating equation models were used to obtain risk estimates and 95% confidence intervals (CIs). Confounding by indication was minimized by adjusting for history of maternal depression/anxiety before pregnancy.
Results: Overall, 143 281 pregnancies were included; PPHN was identified in 0.2% of newborns. Adjusting for maternal depression, and other potential confounders, SSRI use during the second half of pregnancy was associated with an increased risk of PPHN [adjusted odds ratio (aOR) 4.29, 95% CI 1.34, 13.77] compared with non-use of antidepressants; SNRI use during the same time window was not statistically associated with the risk of PPHN (aOR 0.59, 95% CI 0.06, 5.62). Use of SSRIs and SNRIs before the 20th week of gestation was not associated with the risk of PPHN.
Conclusions: Use of SSRIs in the second half of pregnancy was associated with the risk of PPHN. Given our results on SNRIs and the lack of statistical power for these analyses, it is unclear whether SNRI use during pregnancy also increases the risk of PPHN.
Keywords: Pregnancy; SSRI; depression; persistent pulmonary hypertension of the newborn (PPHN); quebec pregnancy cohort; venlafaxine.
© 2016 The British Pharmacological Society.
Figures
Similar articles
-
Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn: An Update Meta-Analysis.J Womens Health (Larchmt). 2019 Mar;28(3):331-338. doi: 10.1089/jwh.2018.7319. Epub 2018 Nov 8. J Womens Health (Larchmt). 2019. PMID: 30407100 Review.
-
Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn.JAMA. 2015 Jun 2;313(21):2142-51. doi: 10.1001/jama.2015.5605. JAMA. 2015. PMID: 26034955 Free PMC article.
-
Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.N Engl J Med. 2006 Feb 9;354(6):579-87. doi: 10.1056/NEJMoa052744. N Engl J Med. 2006. PMID: 16467545
-
Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis.Am J Obstet Gynecol. 2019 Jan;220(1):57.e1-57.e13. doi: 10.1016/j.ajog.2018.08.030. Epub 2018 Aug 28. Am J Obstet Gynecol. 2019. PMID: 30170040
-
Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies.Am J Psychiatry. 2012 Feb;169(2):134-40. doi: 10.1176/appi.ajp.2011.11040553. Am J Psychiatry. 2012. PMID: 22420034 Review.
Cited by
-
Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations.Neurol Int. 2021 Sep 1;13(3):445-463. doi: 10.3390/neurolint13030044. Neurol Int. 2021. PMID: 34564289 Free PMC article. Review.
-
The treatment of depression - searching for new ideas.Front Pharmacol. 2022 Oct 7;13:988648. doi: 10.3389/fphar.2022.988648. eCollection 2022. Front Pharmacol. 2022. PMID: 36278184 Free PMC article. Review.
-
Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques.Ther Adv Psychopharmacol. 2019 Mar 11;9:2045125318818814. doi: 10.1177/2045125318818814. eCollection 2019. Ther Adv Psychopharmacol. 2019. PMID: 30886699 Free PMC article.
-
A Meta-Analysis of the Risk Factors of Persistent Pulmonary Hypertension in Newborns.Front Pediatr. 2021 Oct 29;9:659137. doi: 10.3389/fped.2021.659137. eCollection 2021. Front Pediatr. 2021. PMID: 34778120 Free PMC article.
-
The Association Between Prenatal Exposure to Antidepressants and Autism: Some Research and Public Health Aspects.Front Psychiatry. 2020 Nov 23;11:555740. doi: 10.3389/fpsyt.2020.555740. eCollection 2020. Front Psychiatry. 2020. PMID: 33329095 Free PMC article. Review.
References
-
- Hageman JR, Adams MA, Gardner TH. Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis, and management. Am J Dis Child 1984; 138: 592–595. - PubMed
-
- Abman SH. New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Pediatr Pulmonol Suppl 1999; 18: 201–204. - PubMed
-
- Chambers CD, Hernandez‐Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin‐reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579–587. - PubMed
-
- Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723–1733. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical